Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00090090
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:34:53.384472+00:00
Published At
2008-01-15T00:00:00+00:00
Record Updated At
2008-01-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Mantle Cell Lymphoma", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2008-01-15"
protocolSection.identificationModule.nctId
"NCT00090090"
protocolSection.identificationModule.officialTitle
"A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin\u0027s Lymphoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.